Efficacy and safety of anagrelide as a first‐line drug in cytoreductive treatment‐naïve essential thrombocythemia patients in a real‐world setting

OBJECTIVE: This study aimed to retrospectively assess the efficacy and safety of anagrelide in cytoreduction therapy‐naïve essential thrombocythemia (ET) patients in a real‐world setting. METHOD: Data from 53 ET patients who received anagrelide as a first‐line therapy were reviewed for patient chara...

Descripción completa

Detalles Bibliográficos
Autores principales: Ito, Tomoki, Hashimoto, Yoshinori, Tanaka, Yasuhiro, Nakaya, Aya, Fujita, Shinya, Satake, Atsushi, Nakanishi, Takahisa, Konishi, Akiko, Hotta, Masaaki, Yoshimura, Hideaki, Ishii, Kazuyoshi, Hashimoto, Akiko, Kondo, Toshinori, Omura, Hiromi, Shinzato, Isaku, Tanaka, Takayuki, Nomura, Shosaku
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6851998/
https://www.ncbi.nlm.nih.gov/pubmed/31107982
http://dx.doi.org/10.1111/ejh.13265

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6851998/
https://www.ncbi.nlm.nih.gov/pubmed/31107982
http://dx.doi.org/10.1111/ejh.13265

Ejemplares similares